BERWYN, Pa., Feb. 13, 2020 (GLOBE NEWSWIRE) — Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases, announced today that the Data Safety Monitoring Board has...
Following this clearance, SARA-INT trial to recruit 231 patients vs. 334 initially planned More than 80% of patients are now recruited – completion of patient recruitment expected in Q2 2020 Interim analysis by the study’s data safety and monitoring board (DSMB)...
AUSTIN, Texas, Feb. 11, 2020 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that The Journal of Prevention of Alzheimer’s Disease (JPAD), a peer-reviewed journal...
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that the last patient has undergone the final assessment in its...
Bellwyck Pharma Services Brings Strong Presence in Key Markets, Increasing Breadth of PCI’s Global Network PHILADELPHIA — PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, today announced the acquisition...
Email
Text